Published in Int J Hypertens on May 11, 2011
The efficacy of antihypertensive drugs in chronic intermittent hypoxia conditions. Front Physiol (2014) 0.81
Baroreflex activation therapy for the treatment of drug-resistant hypertension: new developments. Cardiol Res Pract (2012) 0.77
Carotid baroreceptor stimulation: a potential solution for resistant hypertension. Interv Neurol (2014) 0.75
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37
Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76
US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA (2010) 13.94
The diagnosis and treatment of baroreflex failure. N Engl J Med (1993) 3.45
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (2010) 2.38
Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension (2005) 2.23
Baroceptor function in chronic renal hypertension. Circ Res (1956) 2.12
Role of baroreceptor reflex in daily control of arterial blood pressure and other variables in dogs. Circ Res (1973) 1.95
What sets the long-term level of renal sympathetic nerve activity: a role for angiotensin II and baroreflexes? Circ Res (2003) 1.91
Prolonged activation of the baroreflex produces sustained hypotension. Hypertension (2004) 1.86
Baroreflex failure as a late sequela of neck irradiation. Hypertension (2003) 1.54
The effects of bilateral removal of the carotid bodies and denervation of the carotid sinuses in two human subjects. J Physiol (1965) 1.51
Cardiovascular effects of direct stimulation of the carotid sinus nerve in man. Acta Physiol Scand (1958) 1.50
Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension (2007) 1.48
Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension (2006) 1.36
Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension (2009) 1.33
Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. Am J Surg (1967) 1.30
Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension. Am J Physiol Regul Integr Comp Physiol (2000) 1.15
Unloading arterial baroreceptors causes neurogenic hypertension. Am J Physiol Regul Integr Comp Physiol (2002) 1.10
Long-term effects of carotid sinus denervation on arterial blood pressure in humans. Circulation (2002) 1.06
Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. Expert Opin Ther Targets (2009) 1.05
Effects of chronic baroreceptor unloading on blood pressure in the dog. Am J Physiol Regul Integr Comp Physiol (2004) 1.05
Arterial baroreceptor denervation impairs long-term regulation of arterial pressure during dietary salt loading. Am J Physiol (1998) 1.00
Effect of sino-aortic denervation in comparison to cardiopulmonary deafferentiation on long-term blood pressure in conscious dogs. Pflugers Arch (1988) 0.98
Mechanisms of resetting of arterial baroreceptors: an overview. Am J Med Sci (1988) 0.96
Hypertension following arterial baroreceptor denervation in the unanesthetized dog. Circ Res (1981) 0.96
Management of uncontrollable hypertension with a carotid sinus stimulation device. Hypertension (2007) 0.94
Arterial baroreflex and peripheral chemoreflex function after radiotherapy for laryngeal or pharyngeal cancer. Int J Radiat Oncol Biol Phys (2002) 0.92
Pressure to change? Re-evaluating the role of baroreceptors in the long-term control of arterial pressure. Am J Physiol Regul Integr Comp Physiol (2005) 0.92
The frequency-dependent nature of blood pressure regulation by the carotid sinus studied with an electric analog. Circ Res (1958) 0.91
Baroreflex failure syndrome after bilateral excision of carotid body tumors: an underestimated problem. J Vasc Surg (2000) 0.88
Cardiovascular and neuroendocrine responses to baroreceptor denervation in baboons. Am J Physiol (1990) 0.85
Surgical treatment of hypertension with reference to baropacing. Am J Cardiol (1966) 0.85
Bilateral carotid sinus nerve stimulation in the treatment of hypertension. Am J Cardiol (1972) 0.83
Acute device-based blood pressure reduction: electrical activation of the carotid baroreflex in patients undergoing elective carotid surgery. Vascular (2007) 0.82
Baroreflex activation for the treatment of hypertension: principles and practice. Expert Rev Med Devices (2006) 0.82
Regulation of arterial blood pressure by aortic baroreceptors in the unanesthetized dog. Circ Res (1978) 0.82
Absence of sustained hypertension in sinoaortic-denervated rabbits. Am J Physiol (1986) 0.81
Aortic baroreceptor deafferentation in the baboon. J Appl Physiol (1985) (1986) 0.81
The principle of electrical carotid sinus nerve stimulation: a nerve pacemaker system for angina pectoris and hypertension therapy. Ann Biomed Eng (1980) 0.80
Search for optimal frequencies and amplitudes of therapeutic electrical carotid sinus nerve stimulation by application of the evolution strategy. Artif Organs (1989) 0.78
Fatal hypertensive crisis following denervation of the carotid sinus for the relief of repeated attacks of syncope; case history. Bull Johns Hopkins Hosp (1957) 0.78
Improved control of resistant hypertension with device-mediated electrical carotid sinus baroreflex stimulation. J Clin Hypertens (Greenwich) (2007) 0.77
Implantation of a carotid baroreceptor stimulator in patients with pacemakers and hypertension. Pacing Clin Electrophysiol (2011) 0.77
Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology. Ann Vasc Surg (2009) 0.77
Prevention or attenuation of baroreceptor resetting by pulsatility during elevated pressure. Hypertension (1987) 0.76
Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet (2012) 6.29
Exercise-induced pulse wave velocity changes in untreated patients with essential hypertension: the effect of an angiotensin receptor antagonist. J Clin Hypertens (Greenwich) (2014) 2.61
Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet (2008) 2.53
Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. J Hypertens (2010) 2.14
A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol (2006) 2.13
Exercise capacity and mortality in older men: a 20-year follow-up study. Circulation (2010) 1.54
Prognostic effect of exercise capacity on mortality in older adults with diabetes mellitus. J Am Geriatr Soc (2010) 1.52
Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare? Arthritis Rheum (2008) 1.51
Hypertension associated with rhabdomyolysis. J Clin Hypertens (Greenwich) (2007) 1.47
Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A. Arthritis Rheum (2011) 1.46
The reflective writing class blog: using technology to promote reflection and professional development. J Gen Intern Med (2008) 1.46
Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood (2010) 1.44
Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (Greenwich) (2013) 1.44
Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease. J Clin Hypertens (Greenwich) (2009) 1.43
Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. Clin J Am Soc Nephrol (2013) 1.41
Platelets interplay between pneumonia and cardiovascular events: establishing a link? J Am Coll Cardiol (2015) 1.28
Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol (2008) 1.23
Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens (2006) 1.22
Molecular basis of statin-associated myopathy. Atherosclerosis (2008) 1.16
BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. Diabetes Care (2012) 1.14
Racial differences in opioid use for chronic nonmalignant pain. J Gen Intern Med (2005) 1.14
Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther (2014) 1.11
Platelet activation during exercise is not attenuated by inhibition of the renin-angiotensin system: the role of physical activity. J Hypertens (2013) 1.11
Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects. J Androl (2005) 1.10
Exercise capacity and all-cause mortality in African American and Caucasian men with type 2 diabetes. Diabetes Care (2009) 1.08
Exercise capacity and progression from prehypertension to hypertension. Hypertension (2012) 1.08
Cardiovascular risk in psoriatic arthritis: should we focus on hypertension and diabetes only? Clin Exp Rheumatol (2014) 1.08
Retinal arteriolar diameters and incident hypertension in initially normotensive individuals: a masked hypertension effect? J Hypertens (2014) 1.08
Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation (2012) 1.07
Macro and microcirculation damage and incident hypertension: predictors of progression? J Hypertens (2014) 1.07
Does vitamin D really contribute to excess cardiovascular risk in rheumatoid arthritis? Comment on the article by Haque et al. Arthritis Care Res (Hoboken) (2013) 1.07
Exercise-induced platelet activation in essential hypertension: have we solved the puzzle? J Hypertens (2013) 1.06
The enigma of microvascular and macrovascular changes in mild essential hypertension. J Hypertens (2014) 1.06
Assessment of retinal vasculature in pregnancy: unveiling the complex pathogenesis of gestational vascular complications. Hypertension (2013) 1.06
Investigating the association between creatine kinase and failure of antihypertensive treatment: much to be thought of in the everyday clinical setting. J Hypertens (2013) 1.05
Renal sympathetic denervation and systemic hypertension. Am J Cardiol (2010) 1.03
Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications. J Hypertens (2008) 1.03
Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine. Clin Rheumatol (2007) 0.96
Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int (2009) 0.96
Masked hypertension in untreated and treated patients with diabetes mellitus: attractive but questionable interpretations. Hypertension (2013) 0.96
Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl (2006) 0.95
Gender differences in hypertension: myths and reality. Curr Hypertens Rep (2013) 0.95
Renal sympathetic denervation: the jury is still out. Lancet (2010) 0.95
Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension. J Hypertens (2009) 0.94
Body mass index, exercise capacity, and mortality risk in male veterans with hypertension. Am J Hypertens (2012) 0.93
Platelet activation in essential hypertension: implications for antiplatelet treatment. Am J Hypertens (2010) 0.92
Interventional management of resistant hypertension. Lancet (2009) 0.92
Intracerebral hemorrhage as the presenting feature of concurrent pheochromocytoma and paragangliomas. J Clin Hypertens (Greenwich) (2008) 0.92
Evaluation and treatment of resistant or difficult-to-control hypertension. J Clin Hypertens (Greenwich) (2008) 0.92
Antihypertensive treatment and sexual dysfunction. Curr Hypertens Rep (2012) 0.91
Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management. J Clin Rheumatol (2012) 0.91
Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med (2017) 0.91
The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J Clin Hypertens (Greenwich) (2006) 0.90
Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. Eur Heart J (2009) 0.90
Renal sympathetic denervation: renal function concerns. Hypertension (2011) 0.90
Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens (2011) 0.89
Exercise capacity and blood pressure associations with left ventricular mass in prehypertensive individuals. Hypertension (2006) 0.88
Leiomyosarcoma of renal vein, initially resembling pheochromocytoma. Clin Exp Hypertens (2012) 0.88
Combined angiotensin inhibition in diabetic nephropathy. N Engl J Med (2014) 0.88
Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens (2012) 0.88
Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin (2013) 0.87
Exercise capacity and mortality in hypertensive men with and without additional risk factors. Hypertension (2009) 0.87
Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol (2007) 0.86
Exercise capacity and all-cause mortality in prehypertensive men. Am J Hypertens (2009) 0.86
Heart rate recovery, exercise capacity, and mortality risk in male veterans. Eur J Prev Cardiol (2011) 0.86
Surgical management of primary aldosteronism. not everything that shines is gold. Clin Exp Hypertens (2011) 0.85
Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. BMC Nephrol (2013) 0.85
Neighborhood racial composition and availability of asthma drugs in retail pharmacies. J Asthma (2005) 0.85
Treatment of hypertension in the elderly. N Engl J Med (2008) 0.84
Sexual dysfunction in essential hypertension: myth or reality? J Clin Hypertens (Greenwich) (2006) 0.83
The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. Expert Opin Ther Targets (2010) 0.83
Eosinophilic enteritis with ascites in a patient with overlap syndrome. Case Rep Med (2009) 0.83
Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens (2010) 0.82
Stenting for renal-artery stenosis. N Engl J Med (2014) 0.82
The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease. BMC Cardiovasc Disord (2008) 0.82
Hypertension and sexual dysfunction: time to act. J Hypertens (2011) 0.81
Paralysis as first manifestation of primary aldosteronism. Nephrol Dial Transplant (2004) 0.81
Heart rate at rest, exercise capacity, and mortality risk in veterans. Am J Cardiol (2013) 0.81
Prevalence, awareness, treatment and control of hypertension in an elderly population in Greece. Rural Remote Health (2010) 0.81